Longitudinal Assessment of Tau Pathology in Patients with Alzheimer’s Disease Using [18F]THK-5117 Positron Emission Tomography

[18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease

(2015) Ryuichi Harada et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease

(2015) Sagar H. Barage et al.   NEUROPEPTIDES

[18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease

(2013) Chun-Fang Xia et al.   Alzheimers & Dementia

Novel 18F-Labeled Arylquinoline Derivatives for Noninvasive Imaging of Tau Pathology in Alzheimer Disease

(2013) N. Okamura et al.   JOURNAL OF NUCLEAR MEDICINE

Amyloid Imaging with PET in Early Alzheimer Disease Diagnosis

(2013) Christopher C. Rowe et al.   MEDICAL CLINICS OF NORTH AMERICA

Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls

(2013) Masahiro Maruyama et al.   NEURON

National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease

(2012) Bradley T. Hyman et al.   Alzheimers & Dementia

Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer’s disease pathology

(2012) Ryuichi Harada et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature

(2012) Peter T. Nelson et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease

(2011) Victor L. Villemagne et al.   ANNALS OF NEUROLOGY

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease

(2010) C. R. Jack et al.   BRAIN

Alzheimer's disease: strategies for disease modification

(2010) Martin Citron   NATURE REVIEWS DRUG DISCOVERY

The use of PET in Alzheimer disease

(2010) Agneta Nordberg et al.   Nature Reviews Neurology

Challenges in the conduct of disease-modifying trials in ad: Practical experience from a phase 2 trial of TAU-aggregation inhibitor therapy

(2009) C. Wischik et al.   Journal of Nutrition Health & Aging